Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long sequence insertion via CRISPR/Cas gene-editing with transposase, recombinase, and integrase

Current Opinion in Biomedical Engineering(2023)10.1016/j.cobme.2023.100491Source: DataRank Database

Long sequence insertion via CRISPR/Cas gene-editing with transposase, recombinase, and integrase is a research paper published in Current Opinion in Biomedical Engineering (2023). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: greenTopics (8)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Guangxue Xu,William A. Johnson ORCID,Yuanhao Qu ORCID,Di Yin ORCID,Nurupa Ramkissoon

Live enrichment

PubMed:38549686 PMC:PMC10976843

NHGRI NIH HHS

Grant: R35 HG011316

NIGMS NIH HHS

Grant: R01 GM141627

National Institutes of Health

National Institute of Health

greenLicense: https://doi.org/10.15223/policy-004

GREENhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10976843

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10976843/pdf/nihms-1978499.pdf

publisherhttps://api.elsevier.com/content/article/PII:S2468451123000478?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2468451123000478?httpAccept=text/plain

Fields of Study

MedicineBiology

Keywords

RecombinaseTransposaseGenome EditingCrispr/cas9Genomic InsertionLarge Fragment Knock-in

Related Papers (10)

The promise and challenge of therapeutic genome editing

N/A

11.1DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-1978-5

Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing

Nature Communications(2020)

co-cited

10.1038/s41467-020-17029-3

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity

N/A

0.873DataRank · unranked

Cell stem cell(2020)

co-cited

10.1016/j.stem.2020.05.008

A prospective evaluation of serum methionine‐related metabolites in relation to pancreatic cancer risk in two prospective cohort studies

International Journal of Cancer(2020)

co-cited

10.1002/ijc.32994

Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice

Nature Communications(2021)

co-cited

10.1038/s41467-021-22295-w

Cas9-specific immune responses compromise local and systemic AAV CRISPR therapy in multiple dystrophic canine models

N/A

4.2DataRank · unranked

Nature Communications(2021)

co-cited

10.1038/s41467-021-26830-7

Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy

N/A

0.633DataRank · unranked

Molecular Therapy(2021)

co-cited

10.1016/j.ymthe.2021.09.003

Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells

Cell chemical biology(2021)

co-cited

10.1016/j.chembiol.2021.07.011

Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing

Molecular Therapy — Methods & Clinical Development(2021)

co-cited

10.1016/j.omtm.2021.04.009

Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins

N/A

6.9DataRank · unranked

Cell(2022)

co-cited

10.1016/j.cell.2021.12.021